Atlas Trials

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

Clinical trial NCT02651727 · TERMINATED

Trial details

NCT number
NCT02651727
Sponsor
Verastem, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2015-09-01
Primary completion
2017-01-01
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.